insulin glargine + insulin aspart (University of Pennsylvania)

A combination regimen of two insulin analogs used for the management of diabetes mellitus. **Insulin glargine** is a long-acting (basal) human insulin analog that provides a steady background level of insulin over approximately 24 hours. It works by forming micro-precipitates upon subcutaneous injection, which slowly release insulin into the circulation. **Insulin aspart** is a rapid-acting (bolus/prandial) human insulin analog designed to control blood glucose levels around mealtimes. It has a faster onset and shorter duration of action than regular human insulin due to a single amino acid substitution (proline to aspartic acid) that reduces hexamer formation, allowing for quicker absorption. This basal-bolus combination mimics physiological insulin secretion. In clinical research, such as the NCT02144441 trial sponsored by the University of Pennsylvania, this regimen has been evaluated for feasibility in clinician-supported patient self-management of inpatient insulin therapy.

Brand names

LantusBasaglarNovoLogNovoRapid

Other names

glargine + aspartinsulin glargine and insulin aspart